ClinicalTrials.gg
BiologicalDrug

Mogamulizumab clinical trials

Also written KW-0761, Poteligeo and KM8761.

studies test it
32
open now
7
in phase 3
2
first study started
2007

How each study uses mogamulizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the mogamulizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
8 Aug 2018 · POTELIGEO · BLA 761051 (FDA, Drugs@FDA)
European Union
22 Nov 2018 · Poteligeo · EMEA/H/C/004232 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Mogamulizumab
20
Mogamulizumab-kpkc
5
Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer
4

Brand

Poteligeo
12

Development codes

KW-0761
16
KM8761
4
AMG 761
1

Studies by the year they started

32 studies that test it; most in 2023 (4)

Studies that test mogamulizumab, by start year
YearStudies
20071
20092
20103
20111
20123
20131
20141
20153
20162
20171
20181
20202
20212
20222
20234
20243

Who runs them

Industry 17 · Other 15

Kyowa Kirin Co., Ltd. (9) · Kyowa Kirin, Inc. (5) · National Cancer Institute (NCI) (2) · Memorial Sloan Kettering Cancer Center (2) · Kyowa Kirin China Pharmaceutical Co., Ltd. (1) · Osaka University (1) · John Reneau (1) · City of Hope Medical Center (1)

Often tested with

Tested in the same studies.

Recombinant human INTERLEUKIN-15 (1) · Nivolumab (1) · Pembrolizumab (1) · Brentuximab Vedotin (1) · Utomilumab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test mogamulizumab.

Studies

Open first, then newest update. How each study uses mogamulizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 32

See all 32 studies that test mogamulizumab →

Given beside what is tested · 3 — mogamulizumab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with mogamulizumab

Codes

What other systems call mogamulizumab · ClinicalTrials.gg INT005608

  • MeSH (NLM) C549035mogamulizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) YI437801BEMOGAMULIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2054068Confirmed FDA, Wikidata
  • Wikidata Q6890447mogamulizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C62510MogamulizumabOne source FDA
  • DrugBank DB12498One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.